Dilantin (phenytoin) levels fluctuate because the drug has an unusual relationship with your body’s metabolism: unlike most medications, even tiny changes in dose, diet, other medications, or liver function can cause outsized swings in blood concentration. The therapeutic window is narrow, with target levels between 10 and 20 mcg/mL for total phenytoin, so shifts that would be insignificant with other drugs can push you into toxic or sub-therapeutic territory.
Several overlapping factors drive these fluctuations, from the drug’s own chemistry to your genetics, kidney function, and what else you’re taking. Understanding them can help you and your care team keep levels stable.
Nonlinear Metabolism: The Core Problem
Most drugs follow a simple rule: double the dose, double the blood level. Phenytoin breaks that rule. It’s processed by liver enzymes that can only handle so much at once, and within the therapeutic range those enzymes are already approaching their limit. Once they’re close to capacity, a modest dose increase produces a much larger jump in blood concentration than you’d expect. This is called nonlinear, or saturable, metabolism.
In practical terms, raising your daily dose by as little as 30 to 50 mg can sometimes push levels from the middle of the therapeutic range into the toxic zone above 20 mcg/mL. The reverse is also true: a small decrease can cause a disproportionate drop. This makes dose adjustments unusually tricky and is the single biggest reason phenytoin levels seem unpredictable compared to other seizure medications.
Drug Interactions That Raise or Lower Levels
Phenytoin is broken down primarily by two liver enzymes, CYP2C9 and CYP2C19. Any medication that speeds up or slows down those enzymes will shift your phenytoin level, sometimes dramatically.
Fluconazole, a common antifungal, inhibits both CYP2C9 and CYP2C19. Even a short course for a yeast infection can block phenytoin metabolism enough to push levels upward. Fluvoxamine, an antidepressant, strongly inhibits CYP2C19 and can have a similar effect. On the other side, rifampin (used for tuberculosis and some other infections) induces both enzymes, speeding phenytoin clearance and dropping levels.
Valproic acid deserves special mention. It doesn’t just affect metabolism; it physically bumps phenytoin off the blood proteins that carry it. Normally about 90% of phenytoin rides bound to albumin, with only 10% circulating free. When valproic acid displaces some of that bound drug, the free (active) fraction rises. Your total level on a lab report might look normal or even low, while the free level climbs into a range that causes side effects. If you take both medications, your doctor will likely monitor free phenytoin levels (target: 1.0 to 2.0 mcg/mL) rather than relying on the total number.
How Low Albumin Changes the Picture
Because phenytoin clings so heavily to albumin, anything that lowers your albumin level changes how the drug behaves. Albumin drops in many common situations: serious illness, liver disease, major surgery, malnutrition, kidney disease, and prolonged hospitalization. When albumin falls, more phenytoin floats free in the bloodstream.
This creates a confusing lab picture. The total phenytoin level may read low or normal because there’s less protein to hold the drug in circulation, yet the free fraction (the part actually reaching your brain) can be elevated enough to cause toxicity. In one study of critically ill patients with low albumin, those with severe hypoalbuminemia (albumin below 2 g/dL) had median free phenytoin concentrations roughly 60% higher than those with only moderately low albumin. Standard correction formulas exist to estimate free levels from total levels and albumin, but research shows these equations are often inaccurate in individual patients, which is why direct measurement of free phenytoin is more reliable when albumin is low.
Kidney Disease and Uremia
Kidney failure affects phenytoin in two ways. First, waste products that build up in the blood (uremia) compete with phenytoin for albumin binding sites, raising the free fraction in the same way low albumin does. Second, the kidneys normally excrete phenytoin’s main breakdown product after the liver processes it. In patients with kidney failure, clearance of that metabolite drops to roughly one-sixth of normal, which can further complicate how the drug is handled over time.
The net result is similar to the low-albumin scenario: total levels look deceptively low while free levels climb. If you have chronic kidney disease, your care team will typically track free phenytoin rather than total.
Genetic Differences in Metabolism
Your genes determine how efficiently your liver enzymes break down phenytoin, and the variation between people is substantial. Two well-studied genetic variants of the CYP2C9 enzyme, called *2 and *3, produce versions of the enzyme with markedly reduced capacity. In a study comparing patients with at least one of these variants to those with normal enzyme function, carriers of the slower variants needed about 37% less phenytoin to reach therapeutic levels (roughly 199 mg/day versus 314 mg/day).
If you carry one of these variants and receive a standard starting dose, your levels will climb higher and faster than expected. Because phenytoin’s metabolism is already nonlinear, the combination of genetic slow metabolism and saturable enzymes makes toxicity more likely during the early weeks of treatment. Pharmacogenomic testing for CYP2C9 is available and relatively inexpensive, though it’s not yet routine everywhere.
Alcohol Use
Alcohol’s effect on phenytoin depends on whether you’re drinking right now or have been drinking heavily for a long time. In a study of chronic alcoholics without liver damage, phenytoin clearance was significantly lower while they were actively drinking, meaning levels would tend to rise. But once they stopped drinking, clearance jumped by about 43%. The explanation: chronic alcohol exposure revs up liver enzymes over time, but alcohol itself competes for those same enzymes while it’s present. Once you stop drinking, the revved-up enzymes are suddenly free to process phenytoin faster, and levels drop.
For most people with a history of heavy drinking, standard doses of phenytoin produce lower-than-expected blood levels. Binge drinking on top of that pattern can cause levels to spike temporarily, then fall again once the alcohol clears.
Pregnancy
Phenytoin levels commonly fall during pregnancy, sometimes enough to lose seizure control. Research using isotope-labeled drug tracking found that pregnant women cleared phenytoin significantly faster than they did after delivery. The average half-life shortened from about 39 hours postpartum to 31 hours during pregnancy, and the liver’s maximum capacity to eliminate the drug rose from about 780 mg/day to 1,170 mg/day.
Several pregnancy-related changes drive this: expanded blood volume dilutes the drug, increased liver blood flow speeds metabolism, lower albumin raises the free fraction (which the liver then clears more quickly), and hormonal shifts may directly boost enzyme activity. Levels typically return to pre-pregnancy values within a few months after delivery, which means doses increased during pregnancy often need to be reduced again postpartum to avoid toxicity.
Formulation and Absorption Issues
Phenytoin comes in extended-release capsules, chewable tablets, and a liquid suspension. While bioavailability studies comparing the capsules and suspension found no significant difference in healthy volunteers under controlled conditions, real-world absorption can vary. The suspension settles if not shaken thoroughly, which means you could get more or less drug from each dose. Enteral feeding tubes can also reduce absorption if the drug binds to the tubing or if tube feeds alter stomach pH.
Switching between brand-name Dilantin and generic phenytoin can occasionally shift levels, though pharmacokinetic studies suggest the products are equivalent when properly manufactured. The more common culprit is inconsistent timing with food: phenytoin absorption slows when taken with meals, and if your eating pattern changes, the rate at which the drug reaches your bloodstream changes with it.
Why Small Changes Add Up
What makes phenytoin uniquely frustrating is that none of these factors operate in isolation. Nonlinear metabolism amplifies every other variable. A mild stomach bug that reduces absorption for a few days, a new prescription that nudges enzyme activity, or a drop in albumin from a brief illness can each shift levels in ways that would be trivial with a linear drug. With phenytoin, these small pushes land on a steep curve where the relationship between dose and blood level is exponential rather than proportional.
Regular blood monitoring is the most effective way to catch fluctuations early. Many clinicians check levels whenever a new medication is added or stopped, during illness, after dose changes, and at routine intervals even when everything seems stable. If your levels swing despite consistent dosing and no obvious triggers, pharmacogenomic testing or switching to free phenytoin monitoring (rather than total) can sometimes explain the pattern.